Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Kaiser Foundation Research Institute
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01621711
First received: June 11, 2012
Last updated: September 23, 2013
Last verified: September 2013
  Purpose

This component of a larger Center of Research Excellence Grant improves treatment for drug abuse by developing effective linkages between specialty drug treatment and primary health care.


Condition Intervention
Substance Abuse
Substance Dependence
Substance, Addiction
Alcohol Abuse
Behavioral: patient activation intervention

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Number of primary care visits, prevention visits and patient prevention Behaviors [ Time Frame: 24 months post baseline ] [ Designated as safety issue: No ]
  • Number of drug, alcohol and cigarette abstinence days [ Time Frame: 24 months post baseline ] [ Designated as safety issue: No ]
  • Number of patients with significant changes in health and psychosocial measurements [ Time Frame: 24 months post baseline ] [ Designated as safety issue: No ]
  • Amount of emergency room and inpatient costs versus primary care costs [ Time Frame: 24 months post baseline ] [ Designated as safety issue: No ]

Estimated Enrollment: 700
Study Start Date: March 2011
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Usual Primary Care
Usual Primary Care plus Continuing Care
Primary Care plus three continuing care elements: 1) a 1-1/2 hour group session on activation regarding overall health behaviors and a 1-1/2 hour group session on selecting a PC physician and communicating with him/her, and 2) a linkage phone call with the patient, clinician, and PC physician.
Behavioral: patient activation intervention
Delivered by a clinical psychologist: 1) a 1-1/2 hour group session on activation regarding overall health behaviors and 2) a 1-1/2 hour group session on selecting a PC physician and communicating with him/her, and 3) a linkage phone call with the patient, clinician, and PC physician.

Detailed Description:

This is a longitudinal two-arm quasi-experimental 2-month alternating off/on design over a 20 month period in which, after a random start, the Continuing Care condition alternately is added to Usual Care in the clinic and then removed. We compare Usual Care to Usual Care plus Continuing Care. Follow-up interviews will be conducted at 6, 12 and 24 months. The Continuing Care intervention includes Usual Care plus sessions on activation regarding overall health behaviors and on selecting a PC physician and communicating with him/her, and 2) a linkage phone call with the patient, clinician, and Primary Care physician. The linkage conference call is set up as a phone consult appointment in the physician's and clinician's schedules in the EMR. The design also includes a 1-hour informational session for PC physicians during a lunch staff meeting to inform them of the linkage, information on where to find guidelines in the EMR, and also an EMR alert reminder to the PC Physician before the patient's visit. The intervention aims to place drug abuse problems in the context of overall health and health care and to activate patients to increase involvement in their own health care.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Research participants will be adult patients at the Kaiser Permanente San Francisco Chemical Dependency Recovery Program, enrolled in either Day Hospital or Outpatient treatment programs who have completed 1 week of treatment.

Exclusion Criteria:

  • Patients with a diagnosis of dementia, mental retardation, or who are actively psychotic or suicidal will be excluded by their clinician.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01621711

Locations
United States, California
Kaiser Permanente, Chemical Dependency Recovery Program
San Francisco, California, United States, 94115
Sponsors and Collaborators
University of California, San Francisco
Kaiser Foundation Research Institute
Investigators
Principal Investigator: Constance M Weisner, DrPH, LCSW University of California, San Francisco and Kaiser Permanente, Division of Research
  More Information

Additional Information:
Publications:

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01621711     History of Changes
Other Study ID Numbers: 10-01606
Study First Received: June 11, 2012
Last Updated: September 23, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Francisco:
substance abuse
Substance Dependence
Substance, addiction
Alcohol Abuse
prevention and control
preventative health services
patient centered care

Additional relevant MeSH terms:
Substance-Related Disorders
Behavior, Addictive
Alcoholism
Mental Disorders
Compulsive Behavior
Impulsive Behavior
Alcohol-Related Disorders

ClinicalTrials.gov processed this record on July 22, 2014